Press Releases

Jul 29, 2020

Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
- Photos 3
Jul 14, 2020

Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development

* New alliance will use insights from translational and clinical studies to better identify targets, combinations and potential new indications for current medicines
Jul 2, 2020

Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients
Jun 19, 2020

FDA approves new Dupixent® (dupilumab) pre-filled pen designed to support more convenient self-administration

* Single-dose (300 mg) pre-filled pen provides additional administration option to adults and adolescents who are prescribed Dupixent
Jun 15, 2020

Sanofi's emerging oncology pipeline highlighted at the AACR Virtual Annual Meeting II

- Preclinical data show anti-tumor activity in Sanofi's investigational compounds, including an oral selective estrogen receptor degrader (SERD) and an anti-CEACAM5 antibody-drug conjugate

Show per page